Biocon Secures Global Launch Dates for Pebrilzo Following Settlement with Genentech
Biocon Limited secures global launch dates for biosimilar Pebrilzo after settling with Genentech. EU launch set for Q1 2027 and US for Q3 2028 for the cancer drug.
Pharmaceuticals & Biotechnology
Latest Pharmaceuticals & Biotechnology stock news from NSE and BSE filings, 4 stories so far.
Expansion
Shilpa Medicare Subsidiary Commissions Integrated ADC GMP Facility in Dharwad
Shilpa Medicare subsidiary Shilpa Biologicals commissions an ADC GMP facility in Dharwad; the parent company reports a TTM revenue of 1,538.14 crore rupees.
